CGTI. Cell & Gene Innovation Summit 2027
10–11 February 2027 · Location · Berlin · Invited Audience Only
For the patients. We must do better.
Leadership must keep pace to turn living therapies into delivered medicine.
For decision makers from clinical-stage biotech to large pharma.
The cost of goods problem, vector and starting material security, the batch of one and the path from approval to access key critical buying centers now shaping how cell and gene therapy reaches the patient.
01 · CGTI.ai
The batch of one turns every run into a patient.
In 2027 every released batch is a life changed, every lost batch a
window closed, every process decision a clinical one.
Forgetting ends. Compounding begins.
1. The cost of goods problem
A biologics batch is measured in cost per gram. A cell and gene therapy
batch is measured in cost per patient. In 2027 cost of goods becomes the
gate between a therapy that reaches a population and one that reaches a
press release. Manufacturing as afterthought ends. Cost-led design
begins.
2. Vector, vein and starting material
Biologics manufacturing controls its inputs. Cell and gene therapy does
not. In 2027 security of starting material moves from procurement risk
to board-level risk. Capacity-led thinking ends. Supply-led thinking
begins.
3. The batch of one
Biologics industrialised by repetition. Autologous therapy cannot —
every batch is one patient, run once, no second attempt. In 2027 AI and
automation become the line between a released batch and a lost treatment
window. Scale through repetition ends. Scale through intelligence
begins.
4. From approval to access
A biologics approval is a market. A cell and gene therapy approval is a
starting line. In 2027 reimbursement, regional networks and chain of
identity decide whether a therapy reaches the patient. Access engineered
after launch ends. Access designed in begins.
02 · THE GAP
Curated for senior ops & manufacturing leaders
Why it Matters.
Cell therapy at scale.
The science has arrived.
The system has not.
In 2027 the response is operational.
Record capital is moving into CGT facilities and regional networks.
Margins are tight. Vector supply is constrained.
And at the end of every chain is a patient for whom the manufacturing decision is not operational — it is existential.
Three conversations.
One decision.
The question is no longer whether these shifts are coming but how to deploy them in cell and gene therapy without breaking cost, compliance or the patient's window.
03 · WHO IT'S CURATED FOR
Where cell and gene therapy leaders define what reaches the patient.
Human-centred manufacturing systems. Resilient, affordable, inspection- ready supply built for 2027 and beyond.
The people making those decisions are in this room.
MANUFACTURING & OPERATIONS
VP Manufacturing · COO · Site Director · Head of Operations
An invite-only deployment room for leaders from clinical-stage biotech to large pharma.
For operators it is a chance to stress-test strategies with peers facing the same pressures on cost, supply, compliance and the patient at the end of the chain — and need answers they can put into practice in their own facilities.
Quality & Regulatory
VP Quality · Head of QA · Chief Quality Officer · RA Lead
It is a curated, invite-only meeting in Berlin for senior decision makers from cell and gene therapy, biologics and advanced manufacturing who sign off the next wave of capacity, technology and partnership commitments.
MSAT & PROCESS DEVELOPMENT
Head of MSAT · VP Tech Ops · Process Development Lead
Over two days the focus stays on four pillars — the cost of goods problem, vector and starting material, the batch of one and from approval to access — because that is where 2027 decisions are actually made.
DIGITAL, DATA & R&D
Transformation Lead · Heads of R&D · Automation · Infrastructure
For technology providers and CDMOs CGTI is where current cell and gene therapy manufacturing challenges turn into multi-year deployment roadmaps.
Advisory Circle.
Advisory & Past Speakers
For the few.
leaders who sign for cost, compliance and supply
 |
|---|